Cubosomal Lipid Formulation for Combination Cancer Treatment: Delivery of a Chemotherapeutic Agent and Complexed α-Particle Emitter


Journal

Molecular pharmaceutics
ISSN: 1543-8392
Titre abrégé: Mol Pharm
Pays: United States
ID NLM: 101197791

Informations de publication

Date de publication:
01 08 2022
Historique:
pubmed: 19 7 2022
medline: 3 8 2022
entrez: 18 7 2022
Statut: ppublish

Résumé

Here, we propose tailored lipid liquid-crystalline carriers (cubosomes), which incorporate an anticancer drug (doxorubicin) and complexed short-lived α-emitter (bismuth-213), as a strategy to obtain more effective action toward the cancer cells. Cubosomes were formulated with doxorubicin (DOX) and an amphiphilic ligand (DOTAGA-OA), which forms stable complexes with

Identifiants

pubmed: 35849547
doi: 10.1021/acs.molpharmaceut.2c00182
pmc: PMC9346610
doi:

Substances chimiques

Antineoplastic Agents 0
Drug Carriers 0
Ligands 0
Lipids 0
Doxorubicin 80168379AG

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2818-2831

Références

Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2106-19
pubmed: 25070685
Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):614-622
pubmed: 30498897
Eur J Pharm Biopharm. 2016 Jul;104:148-55
pubmed: 27163239
Radiother Oncol. 2004 Dec;73 Suppl 2:S119-22
pubmed: 15971325
J Colloid Interface Sci. 2020 Aug 1;573:176-192
pubmed: 32278949
Langmuir. 2014 Feb 11;30(5):1383-90
pubmed: 24443890
Nanomaterials (Basel). 2019 Apr 19;9(4):
pubmed: 31010165
J Nucl Med. 2018 May;59(5):795-802
pubmed: 29326358
PLoS One. 2014 Feb 07;9(2):e88239
pubmed: 24516620
Cell Death Dis. 2020 Jan 2;11(1):1
pubmed: 31911576
Cardiovasc Drugs Ther. 2017 Feb;31(1):63-75
pubmed: 28185035
Langmuir. 2019 Nov 12;35(45):14532-14542
pubmed: 31635451
Eur J Nucl Med Mol Imaging. 2018 Jul;45(9):1636-1644
pubmed: 29713762
Chempluschem. 2021 May 11;86(7):982-990
pubmed: 33977667
Phys Chem Chem Phys. 2011 Feb 28;13(8):3004-21
pubmed: 21183976
Signal Transduct Target Ther. 2018 Mar 16;3:7
pubmed: 29560283
Langmuir. 2015 Nov 24;31(46):12753-61
pubmed: 26513537
Int J Pharm. 2009 Jan 5;365(1-2):190-9
pubmed: 18790030
Curr Radiopharm. 2018;11(3):200-208
pubmed: 29732998
Biomaterials. 2000 Feb;21(3):223-34
pubmed: 10646938
Chempluschem. 2017 Apr;82(4):570-575
pubmed: 31961592
Pharmacology. 2009;84(5):300-9
pubmed: 19829019
Bioconjug Chem. 2008 Jun;19(6):1274-82
pubmed: 18505278
Int J Mol Sci. 2020 Jul 17;21(14):
pubmed: 32708846
Chem Soc Rev. 2012 Feb 7;41(3):1297-322
pubmed: 21975366
Nanomaterials (Basel). 2020 Jul 13;10(7):
pubmed: 32668687
Langmuir. 2015 Nov 24;31(46):12770-6
pubmed: 26513646
Curr Pharm Des. 2013;19(18):3329-41
pubmed: 23431995
Eur J Nucl Med Mol Imaging. 2012 Dec;39(12):1886-97
pubmed: 22872310
Anticancer Res. 2006 Jul-Aug;26(4B):2841-8
pubmed: 16886603
Eur J Nucl Med Mol Imaging. 2011 Oct;38(10):1788-97
pubmed: 21553086
Nucl Med Biol. 2007 Oct;34(7):779-85
pubmed: 17921029
Mol Pharm. 2020 Sep 8;17(9):3553-3566
pubmed: 32787284
Ther Deliv. 2015;6(12):1347-64
pubmed: 26652281
Mol Imaging Biol. 2010 Apr;12(2):198-203
pubmed: 19543946
Clin Cancer Res. 2010 Nov 1;16(21):5303-11
pubmed: 20858843
Cancer Biol Ther. 2005 Dec;4(12):1318-24
pubmed: 16322682
Bioelectrochemistry. 2006 Sep;69(1):82-7
pubmed: 16443398
Drug Discov Today. 2010 Dec;15(23-24):1032-40
pubmed: 20934534
Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):129-138
pubmed: 30232539
Angew Chem Int Ed Engl. 2019 Mar 4;58(10):2958-2978
pubmed: 29926520
Bioconjug Chem. 2007 Nov-Dec;18(6):2061-7
pubmed: 17935286
Nanomaterials (Basel). 2020 Nov 16;10(11):
pubmed: 33207760
Drug Discov Today. 2016 May;21(5):789-801
pubmed: 26780385
Appl Radiat Isot. 2013 Apr;74:123-7
pubmed: 23416406
Biomaterials. 2017 Jun;130:67-75
pubmed: 28365545
Nanomaterials (Basel). 2020 May 18;10(5):
pubmed: 32443582
Cancer Res. 2010 Sep 1;70(17):6815-23
pubmed: 20651254
Nat Commun. 2015 Nov 17;6:8915
pubmed: 26573367
Blood. 2002 Aug 15;100(4):1233-9
pubmed: 12149203
Adv Colloid Interface Sci. 2017 Nov;249:331-345
pubmed: 28477868
Eur J Pharmacol. 2009 Dec 25;625(1-3):55-62
pubmed: 19836381
Cancer. 2012 Apr 15;118(8 Suppl):2270-6
pubmed: 22488701
J Nucl Med. 2004 Feb;45(2):253-60
pubmed: 14960644
Curr Radiopharm. 2012 Jul;5(3):221-7
pubmed: 22642390
Eur J Nucl Med Mol Imaging. 2018 Jul;45(8):1364-1371
pubmed: 29644393
Nucl Med Biol. 2004 May;31(4):441-9
pubmed: 15093814
Immunotherapy. 2011 Sep;3(9):1041-50
pubmed: 21913827
Cancer Biol Ther. 2007 Jun;6(6):846-52
pubmed: 17495524
Int J Med Sci. 2012;9(3):193-9
pubmed: 22408567

Auteurs

Adrianna Cytryniak (A)

Faculty of Chemistry, University of Warsaw, Pasteura 1, 02-093 Warsaw, Poland.

Kinga Żelechowska-Matysiak (K)

Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland.

Ewa Nazaruk (E)

Faculty of Chemistry, University of Warsaw, Pasteura 1, 02-093 Warsaw, Poland.

Renata Bilewicz (R)

Faculty of Chemistry, University of Warsaw, Pasteura 1, 02-093 Warsaw, Poland.

Rafał Walczak (R)

Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland.

Emilia Majka (E)

Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland.

Adam Mames (A)

Institute of Physical Chemistry, Polish Academy of Sciences, Kasprzaka 44/52, 01-224 Warsaw, Poland.

Frank Bruchertseifer (F)

Directorate for Nuclear Safety and Security, European Commission, Joint Research Centre, Postfach 2340, 76125 Karlsruhe, Germany.

Alfred Morgenstern (A)

Directorate for Nuclear Safety and Security, European Commission, Joint Research Centre, Postfach 2340, 76125 Karlsruhe, Germany.

Aleksander Bilewicz (A)

Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland.

Agnieszka Majkowska-Pilip (A)

Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH